Available Resources

The Childhood Solid Tumor Network (CSTN) at St. Jude offers a comprehensive collection of scientific resources for academic researchers studying pediatric solid tumors and related biology. An overview of available samples and data is provided below; visit our request form for more detailed information. To receive updates on new resources emerging from the CSTN, subscribe to our e-newsletter.

Available resources include:

Preclinical models of childhood solid tumors (GEMMs)

Patient-derived orthotopic xenografts

Genomic, drug sensitivity and pharmacokinetics data


 

Preclinical models of childhood solid tumors (GEMMs)

GEMMs and GEMM-derived tissue samples developed at St. Jude are available for a variety of pediatric solid tumors, including neuroblastoma, retinoblastoma and osteosarcoma. Available strains are detailed on the request form.


 

Patient-derived orthotopic xenografts

Orthotopic xenografts have been created from a wide variety of primary pediatric solid tumors collected under the Molecular Analysis of Solid Tumors (MAST) protocol at St. Jude. Most xenografts express luciferase to enable monitoring of tumor engraftment and progression. Cryopreserved cells, fresh frozen tissue/cells, and formalin-fixed paraffin-embedded tissue blocks are available. See below for the full list of tumor types and samples. Extensive molecular and drug sensitivity data are available for many xenografts. For each of the xenograft samples, a characterization sheet will be provided when shipping samples (see example for SJNBL046_X or visual descriptions of the clonal evolution groups.) Characterization sheets can also be requested.

Neuroblastoma samples

SJ Number Clinical Information Age Stage Status Xenograft Site Known Metastatic Sitec Tx NMYC Amplified Mutation
SJNBL012407_X1 Adrenal resection 10 mo 4 Diagnostic Primary Y Y NRAS
SJNBL013761_X1 Adrenal biopsy 3 yr 4 Diagnostic Primary Bone marrow N N
SJNBL013762_X1 Adrenal resection 15 mo 4 Diagnostic Primary Bone marrow Y Y ALK
SJNBL013763_X1 Adrenal resection 2 yr 2B Diagnostic Primary N Y
SJNBL015724_X1 Adrenal resection 2 yr 4 Diagnostic Primary Bone marrow Y N
SJNBL046_X Adrenal resection 2 yr 4 Diagnostic Primary Y Y
SJNBL108_X Adrenal resection 3 yr 4 Diagnostic Primary Bone marrow Y N

Symbols/Abbreviations: – = not available, mo = months, N = no, Tx = treatment, Y = yes, yr = years.

Osteosarcoma samples

SJ Number Age Sex Status Xenograft Site Location Tx Mutations
SJOS001112_X1 18 yr M Recurrent Primary Lung met N TP53, RB1, ATRX, DLG2
SJOS001121_X1 13 yr M Recurrent Metastatic Hip disarticulation N TP53, RB1
SJOS001127_X1 13 yr M Recurrent Metastatic Lung met N Unknown
SJOS001132_X1 13 yr F Recurrent Metastatic Lung met N TP53, DLG2
SJOS010929_X1 11 yr M Diagnostic Primary Femur N TP53, RB1, ATRX, DLG2
SJOS010930_X1 11 yr F Diagnostic Primary Humerus Y TP53, RB1, DLG2
SJOS012409_X1 9 yr F Diagnostic Primary Femur Y TP53, ATRX, DLG2
SJOS013768_X1 14 yr F Diagnostic Primary Femur Y TP53
SJOS013769_X1 17 yr M Diagnostic Primary Tibia Y DLG2
SJOS016015_X1 17 yr M Diagnostic Primary Femur Y TP53, RB1, DLG2
SJOS016016_X1 7 yr M Recurrent Primary Tibia Y DLG2
SJOS001105_X1 8 yr F Recurrent Metastatic Bone N TP53, DLG2
SJOS001107_X1 13 yr M Unknown Primary Humerus N TP53, DLG2
SJOS001107_X3 14 yr M Recurrent Metastatic Bone N TP53, RB1, DLG2
SJOS001108_X1 14 yr F Unknown Primary Bone N TP53, RB1, DLG2

Symbols/Abbreviations: F = female, M = male, Tx = treatment, yr = years.

Rhabdomyosarcoma samples

SJ Number Subtype Age Sex Status Xenograft Site Location Tx Mutation
SJRHB000026_X1
(Same patient as SJRHB000026_X2)
ERMS 4 yr F Recurrent Primary Pelvis N PIK3CA, HRAS, NOTCH1, CDKN2A, LRP1B
SJRHB000026_X2
(Same patient as SJRHB000026_X1)
ERMS 5 yr F Recurrent Metastatic Stomach Y PIK3CA, HRAS, NOTCH1, CDKN2A, LRP1B
SJRHB010463_X16 ARMS 18 yr M Recurrent Metastatic Lung N PAX3, FOXO1, FGFR1
SJRHB010468_X1 ARMS 13 mo M Diagnostic Primary Thigh Y PAX7, FOXO1
SJRHB010927_X1 ERMS 5 yr F Diagnostic Primary Parapharyngeal mass N NRAS, NF1
SJRHB010928_X1 ERMS 9 yr M Recurrent Primary Prostate Y NOTCH3, CDKN2A, NF1, LRBP1
SJRHB011_X
(Same patient as SJRHB011_Y)
ERMS 5 yr M Diagnostic Primary Neck N PIK3CA, TP53, CDKN2A, LRP1B, SYNE1, FGFR4, CACNA1H
SJRHB011_Y
(Same patient as SJRHB011_X)
ERMS 4 yr M Recurrent Primary Skull Y PIK3CA, TP53, CDKN2A LRP1B, FGFR4, CACNA1H, MUC16, DCC, HGF
SJRHB012_X
(Same patient as SJRHBO12_Y, Z)
ERMS 17 yr M Diagnostic Primary Prostate N Unknown
SJRHB012_Y
(Same patient as SJRHBO12_X, Z)
ERMS 18 yr M Recurrent Primary Prostate Y CARD11, NF1, A2ML1
SJRHB012_Z
(Same patient as SJRHBO12_X, Y)
ERMS 18 yr M Recurrent Primary Prostate/Bladder Y CARD11, A2ML1
SJRHB012405_X1 ERMS 8 yr F Recurrent Primary Abdomen/Pelvis Y TP53, PAX3, LRP1B
SJRHB013_X ERMS 3 yr F Recurrent Primary Perineal/Bladder N NRAS, FGFR1, CHD7
SJRHB013757_X2 ARMS 3 yr F Diagnostic Primary Calf Y PAX7, FOXO1
SJRHB013758_X1
(Same patient as SJRHB013758_X2)
ERMS 4 yr F Diagnostic Primary Abdomen N HRAS, NOTCH3
SJRHB013758_X2
(Same patient as SJRHB013758_X1)
ERMS 5 yr F Recurrent Primary Abdomen Y HRAS, TP53
SJRHB013759_X1 ARMS 19 yr M Recurrent Metastatic Inguinal mass N PAX3, FOXO1
SJRHB015720_X1 Sclerosing subtype 6 yr F Recurrent Primary Masticator/
oropharyngeal region
Y Unknown
SJRHB015721_X1 ERMS 8 yr M Recurrent Metastatic Retroperitoneal mass Y Unknown

Symbols/Abbreviations: ARMS = alveolar rhabdomyosarcoma, ERMS = embryonal rhabdomyosarcoma, F = female, M = male, Tx = treatment, yr = years.

Other samples

SJ Number Type Age  Sex Status Xenograft Site Location Tx Mutation
SJEWS001321_X1 Ewing sarcoma 10 yr M Diagnostic Primary Tibia Y EWSR1, FLI1
SJHGS012410_X1 High grade sarcoma 21 yr F Diagnostic Metastatic Ling N CIC, CREBBP
SJHGS012411_X1 High grade sarcoma 19 yr F Recurrent Primary Thigh N BCL11A, CIC, P300, HMGA2
SJHGS015726_X1
(Same patient as SJHS015726_X2)
High grade sarcoma 12 yr M Recurrent Primary Calf Y CIC, NTRK1
SJHGS015726_X2
(Same patient as SJHS015726_X1)
High grade sarcoma 12 yr M Recurrent Metastatic Lung Y ALK, CIC, NTRK1
SJLPS014753_X1 Liposarcoma 22 yr F Recurrent Metastatic Lung Y ALK, CIC, NTRK1
SJMRT015723_X1 Rhabdoid tumor 1 yr M Recurrent Metastatic Chest wall Y NFIB, PRKAR1A, SMARCB1
SJRB012408_X1* Retinoblastoma* 16 mth F Recurrent Primary Orbit Y Unknown
SJRB012408_X2* Retinoblastoma* 16 mth F Recurrent Metastatic Orbit Y PDE4DIP

*Please note that retinoblastoma sample size is small so tissue distribution may be limited.
Symbols/Abbreviations: F = female, M = male, mth = months, Tx = treatment, yr = years.


 

Genomic, drug sensitivity and pharmacokinetics data

We offer data from molecular and drug sensitivity analyses of diverse pediatric solid tumors, patient-derived orthotopic xenografts and solid tumor cell lines. (Some cell lines are available; see the request form for details.)

While comprehensive raw datasets are not made available prior to publication, we are happy to accommodate many types of data requests to answer specific research questions.

Genomic sequencing and integrated epigenetic profiling have been performed on pediatric solid tumors and patient-derived orthotopic xenografts as part of the St. Jude-Washington University Pediatric Cancer Genome Project and is actively ongoing in St. Jude investigator-led labs. Available data may include:

  • Whole genome sequencing (WGS)
  • Whole exome sequencing (WES)
  • RNA-seq
  • Whole-genome bisulfite sequencing (WGBS)
  • ChIP-seq

High-throughput drug screening (HTS) data are available for many pediatric solid tumor cell lines and orthotopic xenografts, including Ewing sarcoma, neuroblastoma, osteosarcoma, retinoblastoma and rhabdomyosarcoma. In addition, we offer preclinical pharmacokinetics data for a number of high-priority drugs that are being explored for activity against pediatric solid tumors. Current preclinical trial data is uploaded into OpenClinica for long-term data capture. Data from completed preclinical Phase I (tolerability), Phase II (small pilot efficacy study) and Phase III (randomized, placebo controlled) trials are available by request. For more details and descriptions of Phase I, II and III, please see Stewart et al, 2014 Cell Reports.

  1. AZD-1775
    Bortezomib
    Buparlisib
    Carfilzomib
    Dactolisib
    Everolimus
    Fostamatinib
    Ganetespib
    Gedatolisib
    Irinotecan
    Linsitinib

    Methotraxate
    Olaparib
    Palbociclib
    Panobinostat
    Pazopanib
    Selinexor
    Sorafenib
    Talazoparib
    Trametinib
    Veliparib

  2. 5-Fluorodeoxycytidine
    5-Fluorouracil (5-FU)
    6-Mercaptopurine
    6-Thioguanine
    7-Hydroxystaurosporine
    Abiraterone Acetate
    Actinomycin D
    Afatinib
    Alisertib
    Arimidex
    Arry-520
    Artesunate
    Aurorafin
    Axinitib
    Azacitidine
    AZD-1775
    AZD-4547
    AZD-5363
    AZD-7762
    Binimetinib
    Blenoxane
    Bmn673 (Talazoparib)
    Bms-777607
    Bordoxolone
    Bortezomib
    Bosisunib
    Brivudine
    Buparlisib
    Cabazitaxel
    Cabozantinib
    Carfilzomib
    Ceritinib
    Chlorambucil
    Ciclopirox
    Cladribine
    Clofarabine
    Cobimetinib
    Crenolanib
    Crizotinib
    Cyclophosphamide
    Cyt11387
    Cytadren
    Cytidine
    Dabrafenib
    Daclctisib
    Dacogen
    Daraprim
    Dasatinib
    Dexamthasone
    Dfmo
    Dihydroartemisinin (DHA)
    Docetaxol
    Doxorubicin

    ENMD-981693
    Enzalutamide
    Erlotinib
    Etoposide
    Everolimus
    Fedratinib
    Floxuridine
    Fludara
    Fluphenazine HCL
    Fluvastatin
    Foretinib
    Ganetespib
    GDC-0068
    GDC-0199
    GDC-0994
    Gedatolisib
    Gefifinib
    Gemcitabine
    GMX-1778
    Golotimod
    Hydroxychloroquine
    Idronoxil
    Ifosfamide
    Itraconazole
    Ixabepilone
    JQ1
    Lapatinib
    LEE011
    Leflunomide
    LGX-818
    LY2157299
    Masitinib
    Mepacrine
    Methotrexate
    Midostaurin
    Mithramycin
    Mitomycin
    Mitotane
    Mitoxantrone
    MK-2206
    MK-8776
    Motatenib Diphosphate
    Mycophenolate Mofetil Hydrochloride
    Namenda
    Navitoclax
    Neratinib
    Niftfuimox
    Nililonib
    Nimtmuine
    Noscapine
    NSC-617593
    NSC-714598 | NSC-286644

    Obatoclax
    Olaparib
    Omipalisib
    Ouabain
    Pacritnib
    Palbociclib
    Panobinostat
    Pazopanib
    PD 325901
    Pemetrexed Disodium
    Pentostatin
    Pimasertib
    Pioglitazone
    Ponatinib
    Rabusertib
    Raltitrexed
    Regorafenib
    Retinoic Acid
    RG7112
    Romidepsin
    Ruxolitinib
    Selinexor
    Selumetinib
    Sirolimus
    SN-38
    Sorafenib
    Streptozotocin
    Sulindac
    Sunitinib
    Tamibarotene
    Tamoxifen
    Targretin Bexarotene
    Taselisib
    Tazarotene
    Temozolomide
    Temsirolimus
    Tivantinib
    Tivozanib
    Topotecan
    Trametinib
    Trimetrexate
    Trisenox
    Vantndanib
    VE821
    Vemurafenib
    Vinblastine
    Vincristine
    Vinorelbine
    Vismodegib
    Volelartib
    Vorinostat
    Vosaroxin

  3. Vincristine + Irinotecan (Low dose protracted)
    Vincristine + Irinotecan (High dose 5 day dosing)
    Vincristine + Irinotecan + Panobinostat
    Vinorelbine + Cyclophosphamide
    Panobinostat + Bortezomib
    Vincristine + Dactinomycin + Cyclophosphamide
    Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide (MAP/IE)
    Gemicitabine + Docetaxel
    Cyclophosphamide + Doxorubicin + Etoposide
    Cisplatin + Etoposide
    Irinotecan + Temozolomide
    BMN-673 + Irinotecan + Temozolomide
    Olaparib + Irinotecan + Temozolomide
    Veliparib + Irinotecan + Temozolomide

  4. Rhabdomyosarcoma

    SHRHB026_X1:  Vincristine + Irinotecan
    SHRHB026_X1:  Panobinostat
    SHRHB026_X1:  Panobinostat + Bortezomib
    SHRHB026_X1:  Vincristine + Dactinomycin + Cyclophosphamide

    SHRHB026_X2:  Vincristine + Dactinomycin + Cyclophosphamide
    SHRHB026_X2:  Vinorelbine + Cyclophosphamide

    SJRHB010927_X1:  Vincristine + Dactinomycin + Cyclophosphamide

    SJRHB012_Y:  Vincristine + Irinotecan
    SJRHB012_Y:  Panobinostat + Bortezomib

    SJRHB013759_X1:  Vincristine + Irinotecan
    SJRHB013759_X1:  Panobinostat + Bortezomib

    Neuroblastoma

    SJNBL046_X:  Cyclophosphamide + Doxorubicin + Etoposide / Cisplatin + Etoposide
    SJNBL046_X:  OSI-906 + BEZ-235
    SJNBL046_X:  OSI-906 + BKM-120

    NB5:  Cyclophosphamide + Doxorubicin + Etoposide / Cisplatin + Etoposide
    NB5:  OSI-906 + BEZ-235
    NB5:  OSI-906 + BKM-120

    Ewing sarcoma

    ES-8: Irinotecan + Temozolomide
    ES-8: BMN-673 + Irinotecan + Temozolomide
    ES-8: Olaparib + Irinotecan + Temozolomide
    ES-8: Veliparib + Irinotecan + Temozolomide
    EW-8: Irinotecan + Temozolomide
    EW-8: BMN-673 + Irinotecan + Temozolomide
    EW-8: Olaparib + Irinotecan + Temozolomide
    EW-8: Veliparib + Irinotecan + Temozolomide
    ES-6: Irinotecan + Temozolomide
    ES-6: BMN-673 + Irinotecan + Temozolomide
    ES-6: Olaparib + Irinotecan + Temozolomide
    ES-2: Irinotecan + Temozolomide
    ES-2: BMN-673 + Irinotecan + Temozolomide
    ES-3: Irinotecan + Temozolomide
    ES-3: BMN-673 + Irinotecan + Temozolomide

  5. Ewing sarcoma

    ES-8:  PARP inhibitor trial (BMN-673, Olaparib, Veliparib, Irinotecan, Temozolamide)

About the Childhood Solid Tumor Network

Childhood solid tumors are often difficult to study and treat because they are rare and originate in the complex biological context of developing organs. The CSTN was established to disseminate resources and data that have been developed at St. Jude Children’s Research Hospital, with the aim of stimulating basic research and speeding translation to the clinic.

The effort was launched in 2013 by Howard Hughes Medical Institute investigator Michael Dyer, PhD, of St. Jude Developmental Neurobiology, and Alberto Pappo, MD, of St. Jude Oncology.

For more information, contact us: CSTN@stjude.org